CNTB Connect Biopharma Holdings Limited
USHealthcareAs of 2026-07-10 16:00
Why CNTB matters now
Connect Biopharma Holdings Limited (CNTB) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.51 with -5.64% on the session and $158.0M in market capitalization; recent performance reads 1-month -8.68% and YTD -29.08%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-15.1M, and EPS of $-0.27. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.2%.
The latest indexable market news headline is "Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Huang James filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.65
P/S
2623.49
EV/EBITDA
-3.20
DCF Value
$0.66
FCF Yield
-19.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-60312.5%
Net Margin
-58350.0%
ROE
-49.4%
ROA
-49.9%
ROIC
-67.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-15.1M | $-0.27 |
| FY 2025 | $64.0K | $-55.5M | $-1.00 |
| Q2 2025 | $48.0K | $-12.9M | $-0.23 |
| Q4 2024 | $698.0K | $-8.9M | $-0.42 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.67
Target (Median)
$6.00
Target Range
$4.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CN
Exchange
—
Beta
-0.21
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.